Rate of vision loss in neovascular age-related macular degeneration explored
Authors:
- 11 December 2014
- journal article
- research article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 253 (11) , 1859-1865
Abstract
To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Retrospective analysis of 74 treatment-naïve patients (84 eyes) in two centers in Córdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted. In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the vision loss (R2 = 0.55 p < 0.01) and the less improvement following treatment (Pearson coefficient −0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis . The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation. Visual loss awaiting injection intravitreal anti-VEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss.Keywords
This publication has 14 references indexed in Scilit:
- Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS studyClinical Ophthalmology, 2013
- Accessibility as a Conditioning Factor in Treatment for Exudative Age-related Macular DegenerationEuropean Journal of Ophthalmology, 2013
- Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient careEye, 2012
- Time Trends in the Incidence and Causes of Blindness in IsraelAmerican Journal of Ophthalmology, 2012
- A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medicationsEye, 2011
- Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcomeGraefe's Archive for Clinical and Experimental Ophthalmology, 2011
- Guías de práctica clínica de la SERV: Tratamiento de la degeneración macular asociada a la edad (DMAE) exudativaArchivos de la Sociedad Española de Oftalmología, 2009
- The Natural History and Prognosis of Neovascular Age-Related Macular DegenerationOphthalmology, 2008
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Progressive Visual Loss in Subfoveal Exudation in Age-related Macular Degeneration: A Meta-analysis Using Lineweaver-Burke PlotsAmerican Journal of Ophthalmology, 2007